171 related articles for article (PubMed ID: 36610353)
1. Novel chemical-structure TPOR agonist, TMEA, promotes megakaryocytes differentiation and thrombopoiesis via mTOR and ERK signalings.
Jiang X; Sun Y; Yang S; Wu Y; Wang L; Zou W; Jiang N; Chen J; Han Y; Huang C; Wu A; Zhang C; Wu J
Phytomedicine; 2023 Feb; 110():154637. PubMed ID: 36610353
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel megakaryopoiesis enhancer, ingenol, promoting thrombopoiesis through PI3K-Akt signaling independent of thrombopoietin.
Wang L; Zhang T; Liu S; Mo Q; Jiang N; Chen Q; Yang J; Han YW; Chen JP; Huang FH; Li H; Zhou J; Luo JS; Wu JM
Pharmacol Res; 2022 Mar; 177():106096. PubMed ID: 35077844
[TBL] [Abstract][Full Text] [Related]
3. Xanthotoxin, a novel inducer of platelet formation, promotes thrombocytopoiesis via IL-1R1 and MEK/ERK signaling.
Lai J; Li Y; Ran M; Huang Q; Huang F; Zhu L; Wu Y; Zou W; Xie X; Tang Y; Yang F; Wu A; Ge G; Wu J
Biomed Pharmacother; 2023 Jul; 163():114811. PubMed ID: 37156117
[TBL] [Abstract][Full Text] [Related]
4. TMEA, a Polyphenol in
Li H; Jiang X; Shen X; Sun Y; Jiang N; Zeng J; Lin J; Yue L; Lai J; Li Y; Wu A; Wang L; Qin D; Huang F; Mei Q; Yang J; Wu J
Front Cell Dev Biol; 2021; 9():708331. PubMed ID: 34485295
[TBL] [Abstract][Full Text] [Related]
5. Activating SRC/MAPK signaling via 5-HT1A receptor contributes to the effect of vilazodone on improving thrombocytopenia.
Zhou L; Ni C; Liao R; Tang X; Yi T; Ran M; Huang M; Liao R; Zhou X; Qin D; Wang L; Huang F; Xie X; Wan Y; Luo J; Wang Y; Wu J
Elife; 2024 Apr; 13():. PubMed ID: 38573820
[TBL] [Abstract][Full Text] [Related]
6. Hirsutine, a novel megakaryopoiesis inducer, promotes thrombopoiesis via MEK/ERK/FOG1/TAL1 signaling.
Kang Y; Lin J; Wang L; Shen X; Li J; Wu A; Yue L; Wei L; Ye Y; Yang J; Wu J
Phytomedicine; 2022 Jul; 102():154150. PubMed ID: 35569185
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietic effects of CCAAT/enhancer-binding protein β on the early-stage differentiation of megakaryocytes.
Song H; Liu J; Tian X; Liu D; Li J; Zhao X; Mei Z; Yan C; Han Y
Arch Biochem Biophys; 2021 May; 703():108846. PubMed ID: 33744198
[TBL] [Abstract][Full Text] [Related]
8. Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes.
Liu ZJ; Italiano J; Ferrer-Marin F; Gutti R; Bailey M; Poterjoy B; Rimsza L; Sola-Visner M
Blood; 2011 Apr; 117(15):4106-17. PubMed ID: 21304100
[TBL] [Abstract][Full Text] [Related]
9. Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl.
Yoshida H; Yamada H; Nogami W; Dohi K; Kurino-Yamada T; Sugiyama K; Takahashi K; Gahara Y; Kitaura M; Hasegawa M; Oshima I; Kuwabara K
Exp Hematol; 2018 Mar; 59():30-39.e2. PubMed ID: 29274361
[TBL] [Abstract][Full Text] [Related]
10. A Novel Antithrombocytopenia Agent,
Chen W; Zhu L; Wang L; Zeng J; Wen M; Xu X; Zou L; Huang F; Huang Q; Qin D; Mei Q; Yang J; Wang Q; Wu J
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430539
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist.
Xie C; Zhao H; Bao X; Fu H; Lou L
J Cell Mol Med; 2018 Nov; 22(11):5367-5377. PubMed ID: 30156363
[TBL] [Abstract][Full Text] [Related]
12. Hyperhomocysteinemia potentiates megakaryocyte differentiation and thrombopoiesis via GH-PI3K-Akt axis.
Lei W; Liu Z; Su Z; Meng P; Zhou C; Chen X; Hu Z; Xiao A; Zhou M; Huang L; Zhang Y; Qin X; Wang J; Zhu F; Nie J
J Hematol Oncol; 2023 Jul; 16(1):84. PubMed ID: 37501059
[TBL] [Abstract][Full Text] [Related]
13. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
Erhardt JA; Erickson-Miller CL; Aivado M; Abboud M; Pillarisetti K; Toomey JR
Exp Hematol; 2009 Sep; 37(9):1030-7. PubMed ID: 19631713
[TBL] [Abstract][Full Text] [Related]
14. GSK-3β negatively regulates megakaryocyte differentiation and platelet production from primary human bone marrow cells in vitro.
Ono M; Matsubara Y; Shibano T; Ikeda Y; Murata M
Platelets; 2011; 22(3):196-203. PubMed ID: 21231855
[TBL] [Abstract][Full Text] [Related]
15. Targeting a thrombopoietin-independent strategy in the discovery of a novel inducer of megakaryocytopoiesis, DMAG, for the treatment of thrombocytopenia.
Wang L; Liu S; Luo J; Mo Q; Ran M; Zhang T; Li X; Zou W; Mei Q; Chen J; Yang J; Zeng J; Huang F; Wu A; Zhang C; Wu J
Haematologica; 2023 May; 108(5):1394-1411. PubMed ID: 36546424
[TBL] [Abstract][Full Text] [Related]
16. Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside.
Deutsch VR; Tomer A
Br J Haematol; 2013 Jun; 161(6):778-93. PubMed ID: 23594368
[TBL] [Abstract][Full Text] [Related]
17. OP9 bone marrow stroma cells differentiate into megakaryocytes and platelets.
Matsubara Y; Ono Y; Suzuki H; Arai F; Suda T; Murata M; Ikeda Y
PLoS One; 2013; 8(3):e58123. PubMed ID: 23469264
[TBL] [Abstract][Full Text] [Related]
18. Alnustone promotes megakaryocyte differentiation and platelet production via the interleukin-17A/interleukin-17A receptor/Src/RAC1/MEK/ERK signaling pathway.
Li Y; Lai J; Ran M; Yi T; Zhou L; Luo J; Liu X; Tang X; Huang M; Xie X; Li H; Yang Y; Zou W; Wu J
Eur J Pharmacol; 2024 May; 971():176548. PubMed ID: 38570080
[TBL] [Abstract][Full Text] [Related]
19. Branched-chain amino acids promote thrombocytopoiesis by activating mTOR signaling.
Jiang H; Zhang L; Yang M; Li G; Ding C; Xin M; Dai J; Sun X; Fan X; Sun H; Liu J; Xu Y
J Thromb Haemost; 2023 Nov; 21(11):3224-3235. PubMed ID: 37473846
[TBL] [Abstract][Full Text] [Related]
20. Targeting TLR2/Rac1/cdc42/JNK Pathway to Reveal That Ruxolitinib Promotes Thrombocytopoiesis.
Yang S; Tang X; Wang L; Ni C; Wu Y; Zhou L; Zeng Y; Zhao C; Wu A; Wang Q; Xu X; Wang Y; Chen R; Zhang X; Zou L; Huang X; Wu J
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
